Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results
July 17 2023 - 11:04AM
Dow Jones News
By Chris Wack
Argenx shares were up 30% to $492.01 Monday after the immunology
company said it saw positive topline results from its study with
biopharmaceutical company Zai Lab evaluating Vyvgart Hytrulo, or
efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic
inflammatory demyelinating polyneuropathy.
Argenx stock hit its 52-week high of $498.63 earlier in the
session and is up 35% over the past 12 months. Zai Lab shares were
up 8% to $30.17.
The companies said the study met its primary endpoint,
demonstrating a significantly lower risk of relapse with Vyvgart
Hytrulo compared with placebo.
The study showed that the safety and tolerability profile was
consistent with the confirmed safety profile of Vyvgart, and 91% of
eligible patients continued to the next phase of the open-label
extension study.
The most frequent treatment-related adverse event was injection
site reactions, which occurred in a lower percentage of patients
than previous Vyvgart Hytrulo trials. All injection site reactions
were mild to moderate and resolved over time.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 17, 2023 10:49 ET (14:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Apr 2024 to May 2024
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From May 2023 to May 2024